4519.T

Equity

CHUGAI PHARMACEUTICAL CO

Health Care · Drug Manufacturers - General

$10,455.00

+10,455.00 (+0.00%)

Open

N/A

Day Range

$10,375.00 - $10,570.00

52W Range

$5,942.00 - $10,700.00

Volume

3M

Price History

Key Statistics

Market Cap

N/A

P/E Ratio

N/A

EPS

N/A

Dividend Yield

N/A

P/B Ratio

N/A

Payout Ratio

N/A

ROE

N/A

Debt/Equity

N/A

Peers in Health Care

Symbol Name Price Mkt Cap Div Yield Change
ACAD ACADIA Pharmaceuticals Inc. $24.56 N/A - +0.00%
ABT Abbott Laboratories $116.35 N/A 2.06% +0.00%
AKBA Akebia Therapeutics, Inc. $1.31 N/A - +0.00%
ACB Aurora Cannabis Inc. $3.84 N/A - +0.00%
CRSP CRISPR Therapeutics AG $60.14 N/A - +0.00%
A Agilent Technologies, Inc. $121.38 N/A 0.82% +0.00%
AHCO AdaptHealth Corp. $9.15 N/A - +0.00%
ABBV AbbVie Inc. $232.08 N/A 2.87% +0.00%

Community Sentiment

Sign in to vote

0% Bullish 0% Neutral 100% Bearish

0 votes

Discussion (0)

Sign in to join the discussion

Loading comments...

About CHUGAI PHARMACEUTICAL CO

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Polivy, Tecentriq, and Phesgo; Neutrogin and Sigmart; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; and research and license agreement with Gero PTE. LTD. to develop novel therapies for age-related diseases. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.

www.chugai-pharm.co.jp →

Dividend Safety

Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.

50

Borderline

Based on 4 fundamental factors

Analysis Tools

Sign in for analysis tools

Share